Floatz logo

Therapeutic Asset Ratings

1,045 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Trastuzumab Deruxtecan
HER2-low Expressing Breast Cancer
SWOG Cancer Research NetworkP4BBB (77)
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
AstraZenecaP3BBB (76)
Trastuzumab Deruxtecan
Advanced Breast Carcinoma
SWOG Cancer Research NetworkP4BBB (75)
Brentuximab Vedotin
T-Cell Lymphoma
Yale UniversityP4BBB (73)
Brentuximab Vedotin
Lymphoma, Large-Cell, Anaplastic
Seagen Inc.P3BBB (72)
Brentuximab Vedotin
Cutaneous T-cell Lymphoma (CTCL)
Assistance Publique - Hôpitaux de ParisP3BB (70)
Mirvetuximab Soravtansine
Fallopian Tube Cancer
AbbVieP3BB (70)
Mirvetuximab Soravtansine
Primary Peritoneal Cancer
AbbVieP3BB (70)
Sigvotatug Vedotin
Carcinoma, Non-Small Cell Lung
PfizerP3BB (70)
Trastuzumab Duocarmazine
Metastatic Breast Cancer
Byondis B.V.P3BB (70)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Metastatic Urothelial Carcinoma
Vasgene Therapeutics, IncP2/3BB (70)
Inotuzumab Ozogamicin
Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow UniversityP4BB (69)
rc48-adc
Non Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.P4BB (69)
Polatuzumab Vedotin
Diffuse Large B-Cell Lymphoma
Beth Israel Deaconess Medical CenterP3BB (69)
Polatuzumab Vedotin
Refractory Diffuse Large B-Cell Lymphoma
Ruijin HospitalP3BB (69)
Brentuximab Vedotin
Hodgkin Lymphoma
University of CologneP4BB (68)
Inotuzumab Ozogamicin
B Acute Lymphoblastic Leukemia
Charite University, Berlin, GermanyP4BB (68)
Brentuximab Vedotin
Mycosis Fungoides
University of Alabama at BirminghamP3BB (68)
Mirvetuximab Soravtansine
Peritoneal Cancer
AbbVieP3BB (68)
Polatuzumab Vedotin
Large B-Cell Lymphoma (LBCL)
Ruijin HospitalP3BB (68)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Ureteral Neoplasms
Eli Lilly and CompanyP2BB (68)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urinary Bladder Neoplasms
Eli Lilly and CompanyP2BB (68)
Brentuximab Vedotin
Primary Cutaneous Anaplastic Large Cell Lymphoma
John ReneauP3BB (67)
Gemtuzumab Ozogamicin
Acute Myeloid Leukemia
German Cancer Research CenterP3BB (67)
Gemtuzumab Ozogamicin
Myelodysplastic Syndrome
National Cancer Institute (NCI)P3BB (67)
Showing 1 to 25 of 1,045 assets
PreviousPage 1 of 42Next